Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enhancing the response to interferon-alpha.

F Begemann1, H Jablonowski

  • 1I. Medical Department, St. Georg General Hospital, Hamburg, Germany.

Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology
|July 16, 1999
PubMed
Summary

Interferon-alpha (IFN-alpha) combined with ribavirin significantly improves treatment outcomes for chronic hepatitis C (CHC) compared to IFN-alpha alone. This combination therapy, along with tailored schedules for AIDS-associated Kaposi's sarcoma (AIDS-KS), offers better strategies for managing these viral infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: A combination of electrochemistry and mass spectrometry to monitor the interaction of reactive species with supported lipid bilayers.

Scientific reports·2021
Same author

A combination of electrochemistry and mass spectrometry to monitor the interaction of reactive species with supported lipid bilayers.

Scientific reports·2020
Same author

[Stigmatization, metabolic trouble, drug resistance: current challenges in HIV therapy].

MMW Fortschritte der Medizin·2009
Same author

[Epidemiology of the HIV infection].

MMW Fortschritte der Medizin·2009
Same author

[Diagnostic algorithm for HIV-seropositive patients. What you have to keep in mind].

MMW Fortschritte der Medizin·2008
Same author

[Drugs for antiretroviral therapy. The costs of HAART].

MMW Fortschritte der Medizin·2008

Area of Science:

  • Virology and immunology focusing on viral dynamics and host immune responses.
  • Clinical virology evaluating antiviral treatment efficacy and failure.
  • Oncology and infectious diseases, particularly HIV-related complications.

Background:

  • Interferon-alpha (IFN-alpha) initially showed promise as an antiviral, later demonstrating efficacy against certain neoplasms like AIDS-associated Kaposi's sarcoma (AIDS-KS).
  • Disruptions in the endogenous IFN-alpha system are implicated in HIV-positive individuals, influencing KS virulence.
  • IFN-alpha was a primary therapy for chronic hepatitis C (CHC), but monotherapy yielded limited sustained virological response (around 30%).

Framework:

  • A kinetic model of HCV infection, adapted from HIV-1 studies, predicts IFN-alpha treatment outcomes.
  • The model analyzes viral clearance rates based on varying IFN-alpha dosages.
  • It quantifies the impact of different IFN-alpha doses on HCV production/release.

Related Experiment Videos

Implementation:

  • A kinetic model demonstrated that daily IFN-alpha dosing of 5 mIU/day blocks approximately 81% of HCV production, while 10 or 15 mIU/day blocks about 95%.
  • Clinical data confirm superior outcomes with combination therapy (IFN-alpha and ribavirin) versus IFN-alpha monotherapy for CHC.
  • In CHC patients relapsing after IFN-alpha monotherapy, combination therapy achieved a 10-fold higher sustained response rate.

Implications:

  • Combination therapy with IFN-alpha and ribavirin significantly enhances sustained virological response in CHC, particularly for genotypes 2 and 3 (>60%).
  • Extended combination treatment (48 weeks) improves outcomes for genotype 1 CHC patients, increasing sustained response from 17% to 29%.
  • Understanding viral dynamics and host immunity is crucial for optimizing IFN-alpha-based therapies for viral persistence, with tailored approaches for CHC and AIDS-KS.